A Study of SHR6390 in Advanced Solid Tumor Patients

NCT02684266 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm

Interventions

DRUG: SHR6390

Sponsor

Jiangsu HengRui Medicine Co., Ltd.